Johnson & Johnson JNJ
NYSE JNJ
$266.34 -0.74 (-0.28%)
As of: Sep 10, 2026 · 3:59 PM EDT

Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Total Non-Current Liabilities came in at $106.0 billion in Q2 2026, down 6.83% year-over-year from $113.8 billion in Q2 2025, and down 3.21% quarter-over-quarter from $109.5 billion in Q1 2026.

Analysis

Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $106.0 billion for Q2 2026.

  • In Q2 2026, Total Non-Current Liabilities fell 6.83% year-over-year to $106.0 billion; the TTM figure through Jun 2026 stood at $106.0 billion (down 6.83% YoY), while the FY2025 annual figure was $107.8 billion, changed 0.37% from the prior year.
  • Total Non-Current Liabilities came in at $106.0 billion for Q2 2026 at Johnson & Johnson, down from $109.5 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $124.0 billion in Q2 2023 to a low of $93.7 billion in Q4 2023.
  • Average Total Non-Current Liabilities over 5 years is $106.8 billion, with a median of $107.4 billion recorded in 2024.
  • Year-over-year, Total Non-Current Liabilities rose 20.16% in 2023 and slipped 18.66% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $100.0 billion in 2022, then retreated by 2.31% to $97.7 billion in 2023, then grew by 9.93% to $107.4 billion in 2024, then rose by 0.37% to $107.8 billion in 2025, then dropped by 1.68% to $106.0 billion in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $106.0 billion in Q2 2026, $109.5 billion in Q1 2026, and $107.8 billion in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 641.14 Bn 620.38 Bn 17.26 Bn 105.99 Bn
2 AbbVie 451.04 Bn 444.47 Bn 12.70 Bn 106.45 Bn
3 Merck 357.43 Bn 350.29 Bn 12.21 Bn 16.16 Bn
4 Novartis Ag 266.73 Bn 259.04 Bn 11.24 Bn 48.34 Bn
5 Pfizer 157.52 Bn 145.82 Bn 10.94 Bn 100.86 Bn
6 Sanofi 52.14 Bn 44.76 Bn 10.79 Bn 32.04 Bn
7 Revolution Medicines 42.88 Bn 42.88 Bn - 1.53 Bn
8 Incyte 24.70 Bn 20.16 Bn 1.57 Bn 1.40 Bn
9 United Therapeutics 21.47 Bn 18.80 Bn 683.80 Mn 607.80 Mn
10 Neurocrine Biosciences 15.82 Bn 15.43 Bn 935.80 Mn 1.37 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 28, 2026 105.99 Bn
Mar 29, 2026 109.50 Bn
Dec 28, 2025 107.80 Bn
Sep 28, 2025 103.61 Bn
Jun 29, 2025 113.76 Bn
Mar 30, 2025 114.33 Bn
Dec 29, 2024 107.40 Bn
Sep 29, 2024 106.91 Bn
Jun 30, 2024 108.30 Bn
Mar 31, 2024 100.83 Bn
Dec 31, 2023 97.69 Bn
Oct 1, 2023 93.66 Bn
Jul 2, 2023 114.14 Bn
Apr 2, 2023 123.96 Bn
Jan 1, 2023 109.45 Bn
Oct 2, 2022 100.00 Bn
Jul 3, 2022 100.83 Bn
Apr 3, 2022 103.16 Bn
Jan 2, 2022 107.46 Bn
Oct 3, 2021 108.34 Bn